A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

← catalyst calendar

NCT07737717 · readout in 407 d

Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Prevention

Enrollment

84estimated

Sites

Country

Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-31

actual

When the study began enrolling

Primary completion

2027-09-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-09-30

estimated

The whole study's end, after follow-up

First posted

2026-07-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

Interventions

Biological: mRNA-1469
Biological: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

measured Up to Day 7 (the day of study intervention and 6 subsequent days)

Number of Participants with Unsolicited Adverse Events (AEs)

measured Up to Day 28 (the day of study intervention and 27 subsequent days)

Number of Participants with Medically Attended Adverse Events (MAAEs)

measured Up to Day 169 (6 months follow-up after injection)

Number of Participants with Serious Adverse Events (SAEs), Any AEs Leading to Discontinuation From Study Participation and/or Study Vaccination, and AEs of Special Interest (AESIs)

measured Up to End of Study (EOS) (Day 337)

Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed